Research Paper Volume 12, Issue 9 pp 8565—8582

Implications of maraviroc and/or rapamycin in a mouse model of fragility

Figure 3. Biochemical and parameters related to muscle: Muscle and serum myostatin, CK, quadriceps and gastrocnemius weight, muscle cholesterol and triglyceride content. (A) A significant decrease in muscle myostatin levels was recorded in RAPA and MVC+RAPA groups. (B) There was a significative decrease in serum myostatin levels in all the therapeutic groups. (C) CK was significantly reduced in MVC and RAPA groups. No differences were observed after comparing the different groups for (D) quadriceps or (E) gastrocnemius weight. (F) Muscle cholesterol content was significantly higher in the RAPA groups. (G) Although muscle triglyceride content was lower in all the therapeutics groups, no differences were observed. Each bar represents the mean ± SEM. *p <0.05, **p <0.01 and ***p <0.001 with respect to control. CT, cholesterol total. CK, creatinkinase. MVC, maraviroc. MVC+RAPA, maraviroc plus rapamycin. RAPA, rapamycin. TGD, triglyceride.